Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

A recent study by the University of Turku and the University of Helsinki in Finland and the Finnish Social Insurance ...

Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...